title: The influence of concordant xenografts on the humoral and cell-mediated immune responses to subsequent allografts in primates.
abstract: The humoral and cell-mediated immune responses to subsequent allografts were determined in primate recipients after concordant xenotransplantation as a bridge to allotransplantation. Heterotopic heart transplants (n = 4) were performed from cynomolgus monkeys into ABH type-matched olive baboons followed 2 weeks later by allotransplantation from ABH type-matched baboon donors. Allografts were explanted at 8 weeks. All recipients underwent splenectomy at the time of xenotransplantation and received immunosuppression with cyclosporine, azathioprine, and methylprednisolone. Concordant xenotransplantation in these primates did not induce humoral or cell-mediated immune responses that jeopardized subsequent allografts. The degree of xenospecific immune reactivity, as determined by specific cytotoxicity of recipient T-cell lines derived from the xenograft and extent of histologic xenograft rejection, did not predict the severity of subsequent allograft rejection. In two of the four recipients, xenotransplantation induced an alloreactive humoral response against antigens expressed by the B cells of more than 50% of members from a panel of 12 unrelated baboons. In all recipients, priming with xenogeneic splenocytes in vitro induced an accelerated proliferative T-cell response to allogeneic lymphocytes from 16% of this panel. This study affirms the role of concordant xenografts as appropriate biologic bridges to human allotransplantation. However, our results suggest that xenoreactive baboon memory CD4 T cells may recognize major histocompatibility complex class II--like structures shared between the xenogeneic and allogeneic targets. The potential allorecognition induced by a xenograft may affect the process of subsequent allograft donor selection.
authors.affiliation: Department of Surgery, Columbia-Presbyterian Medical Center, New York, N.Y. 10032, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Michler
authors.forename: A S
authors.initials: AS
authors.lastname: Shah
authors.forename: S
authors.initials: S
authors.lastname: Itescu
authors.forename: D P
authors.initials: DP
authors.lastname: O'Hair
authors.forename: S
authors.initials: S
authors.lastname: Tugulea
authors.forename: P A
authors.initials: PA
authors.lastname: Kwiatkowski
authors.forename: Z
authors.initials: Z
authors.lastname: Liu
authors.forename: J L
authors.initials: JL
authors.lastname: Platt
authors.forename: E A
authors.initials: EA
authors.lastname: Rose
authors.forename: N
authors.initials: N
authors.lastname: Suciu-Foca
mesh_terms: D000818:Animals; D000917:Antibody Formation; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection; D016027:Heart Transplantation / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008252:Macaca fascicularis; D010215:Papio; D013601:T-Lymphocytes / Q000276:immunology; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D000949:Histocompatibility Antigens Class II